Insmed
Clinical trials sponsored by Insmed, explained in plain language.
A biopharmaceutical company focused on serious rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaled powder shows promise for Long-Term PAH control Results expected Dec 2026 (estimated) May already have reported ↗
- Liver health may change how body handles inhaled lung drug Results expected Feb 2027 (estimated) May already have reported ↗
- Could a new oral drug pass its first safety hurdle? Results expected Mar 2027 (estimated)
-
New inhaled powder shows promise for Long-Term PAH control
Disease control OngoingThis study is testing the long-term safety and tolerability of an inhaled treprostinil powder (TPIP) in people with pulmonary arterial hypertension (PAH). About 91 participants who completed earlier TPIP studies will receive the drug for up to several years. Researchers will moni…
Phase 2/3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug brensocatib offered to bronchiectasis patients who completed key trial
Disease control ApprovedThis study provides early access to brensocatib, an experimental tablet, for people with non-cystic fibrosis bronchiectasis who finished the ASPEN trial. Participants must have already taken brensocatib without serious side effects. The goal is to offer continued treatment while …
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC